39.41 +0.17 (0.43%)
After hours: 4:10PM EDT
|Bid||39.20 x 1000|
|Ask||499.00 x 1000|
|Day's Range||39.02 - 40.08|
|52 Week Range||33.51 - 61.23|
|Beta (3Y Monthly)||2.17|
|PE Ratio (TTM)||70.20|
|Earnings Date||Nov 6, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||64.14|
Zacks.com featured highlights include: B2Gold, Burlington Stores, FibroGen, Matrix Service Company and Great Lakes Dredge & Dock
Profitability analysis is one of the best ways to evaluate the prospects of a company. It is used in detecting a profitable company over a loss-making one.
SAN FRANCISCO, Oct. 11, 2019 -- FibroGen, Inc. (NASDAQ: FGEN), today announced that results from the global Phase 3 roxadustat clinical program will be presented at the.
FibroGen, Inc. (FGEN) is pleased to announce that William G. Kaelin, Jr., who serves on the company’s Scientific Advisory Board, has been awarded the 2019 Nobel Prize in Physiology or Medicine. The Nobel Assembly announced this morning that the 2019 Nobel Prize in Physiology or Medicine would be awarded jointly to William G. Kaelin, Jr., Sir Peter J. Ratcliffe, and Gregg L. Semenza for their discoveries of how cells sense and adapt to oxygen availability.
FibroGen, Inc. (FGEN) today announced that roxadustat received the 2019 Dushu Lake Prize 独墅湖杯in China for “On-Market Innovative Drug with Highest Clinical Value.” The award was received by its subsidiary FibroGen (China) Medical Technology Development Company, Ltd., of Beijing. The Dushu Lake Prize is one of the highest honors awarded each year within the China’s pharmaceutical industry. It recognizes achievements by companies, researchers, and individuals in the advancement of innovative drug development, and supports the country’s strategy to transform its key industries from “Made in China” to “Innovated in China.” This is the fourth year the award was presented by the China Pharmaceutical Innovation and Research Development Association (PhIRDA 中国医药创新促进会 or 药促会), a national level non-profit organization registered under the Ministry of Civil Affairs.
-- Novel Human Antibody Targets CTGF, A Central Mediator in Fibrosis -- SAN FRANCISCO, Sept. 30, 2019 -- FibroGen, Inc. (NASDAQ: FGEN) today announced publication in The.
FibroGen (FGEN) doses the first patient in a phase II study on roxadustat for the treatment of anemia in cancer patients receiving chemotherapy.
Tyme (TYME) initiates the pivotal stage of the TYME-88-Panc study evaluating oral SM-88 (racemetyrosine) for third-line treatment of patients with metastatic pancreatic cancer.
FibroGen, Inc. (FGEN) today announced first patient dosed in the company’s Phase 2 clinical study of roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of chemotherapy-induced anemia (CIA) in cancer patients receiving chemotherapy. “There is a significant unmet need among cancer patients experiencing anemia,” said John Glaspy, M.D., M.P.H., professor of medicine and co-chair of the Division of Hematology/Oncology at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA).
The CHMP recommends Aerie's (AERI) marketing application for Rhokiinsa to reduce elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.
FibroGen's (FGEN) Evrenzo (roxadustat) wins a marketing approval in Japan for treating anemia caused by chronic kidney disease in dialysis-dependent patients.
SAN FRANCISCO and TOKYO, Sept. 20, 2019 -- FibroGen, Inc. (Nasdaq: FGEN, Interim CEO: James A. Schoeneck, “FibroGen”) and Astellas Pharma Inc. (TSE: 4503, President and CEO:.
TOKYO and SAN FRANCISCO , Sept. 20, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, Interim CEO: ...
Crinetics Pharmaceuticals (CRNX) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Theravance's (TBPH) investigational JAK inhibitor TD-8236 demonstrates favorable results from a phase I study for treating inflammatory lung diseases.
Endo International (ENDP) files BLA for collagenase clostridium histolyticum (CCH) for the treatment of cellulite in the buttocks.